H1 2026 clinical trials: China, funding and technology set the agenda

May 20, 2026 - 08:05

As the first half of 2026 comes to a close, industry experts gathered at Arena International's OCT East Coast conference to break down the forces driving clinical research. Three major themes emerged: the rising influence of Chinese trial sites, a shifting funding landscape, and the accelerating role of technology.

China's presence in global clinical development has grown sharply. Sponsors are increasingly drawn to the country's large patient populations, fast enrollment timelines, and evolving regulatory framework. This shift is not just about cost savings anymore. It reflects a strategic move to access diverse genetic data and capture early market insights for drugs aimed at both local and global approval.

Funding remains a mixed bag. While venture capital has tightened compared to the boom years of 2020 and 2021, government grants and partnerships with large pharma are filling the gap. Experts noted a clear trend toward "smart spending" -- investors want proof of concept earlier, and they are backing trials that use adaptive designs to cut costs and time.

Technology is no longer a nice-to-have. Decentralized trial tools, from wearable sensors to remote monitoring platforms, have become standard. Artificial intelligence is being used to identify ideal trial sites and predict patient dropout rates. However, panelists warned that tech adoption still lags in smaller sites due to infrastructure costs.

The consensus was clear: the clinical trial model is evolving rapidly, and those who fail to adapt to these three pillars -- China's role, disciplined funding, and digital integration -- risk falling behind.